감염증용 임상 검사 분자진단 시장 : 전략과 동향 - 용도별, 장소별, 국가별 예측 - 시장 분석 및 경영진 가이드 포함(2025-2029년)

OVERVIEW:

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis

2. Introduction and Market Definition

• 2.1. Market Definition
  • 2.1.1. Market Size
  • 2.1.2. Currency
  • 2.1.3. Years
• 2.2. Methodology
  • 2.2.1. Methodology
  • 2.2.2. Sources
  • 2.2.3. Authors
• 2.3. Perspective: Healthcare Spending
  • 2.3.1. Global Healthcare Spending
  • 2.3.2. Spending on Healthcare and Pharmaceuticals
  • 2.3.3. Spending on Diagnostics
  • 2.3.4. Important Role of Insurance for Medical Services
• 2.4. The Nature of the IVD Product
  • 2.4.1. Features Overview
  • 2.4.2. The Misunderstood Feature
  • 2.4.3. Regulation
  • 2.4.4. The Newest Feature
  • 2.4.5. The Oldest Feature
  • 2.4.6. All About Scope
  • 2.4.7. Why Turnaround is Becoming More Important
  • 2.4.8. The Role of Trust
• 2.5. The IVD Product of the Future

3. Infectious Diseases - Guide to the Pathogens

• 3.1. Infectious Disease Pathogens - The Big Picture
  • 3.1.1. Viruses
  • 3.1.2. Bacteria
  • 3.1.3. Fungi
  • 3.1.4. Parasites
  • 3.1.5. Prions
  • 3.1.6. Virulence
  • 3.1.7. Transmission
• 3.2. The Coronavirus
  • 3.2.1. Severe acute respiratory syndrome (SARS)
  • 3.2.2. Middle East respiratory syndrome (MERS)
  • 3.2.3. COVID-19. The SARS CoV 2 Virus.
    • 3.2.3.1. Signs and symptoms
    • 3.2.3.2. Transmission
    • 3.2.3.3. Diagnosis
    • 3.2.3.4. Prevention
    • 3.2.3.5. Management
    • 3.2.3.6. Prognosis

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body
• 4.2. The Clinical Laboratory Market Segments
  • 4.2.1. Traditional Market Segmentation
  • 4.2.2. Laboratory Focus and Segmentation
  • 4.2.3. Segmenting the Syndromic Testing Market
• 4.3. Industry Structure
  • 4.3.1. Hospital Testing Share
  • 4.3.2. Economies of Scale
  • 4.3.3. Hospital vs. Central Lab
  • 4.3.4. Physician Office Lab's
  • 4.3.5. Physician's and POCT

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. The Nucleic Acid Impact
  • 5.1.2. Population Dynamics
  • 5.1.3. The Developing World
  • 5.1.4. Decentralization
  • 5.1.5. Self Testing
  • 5.1.6. The Need for Speed
• 5.2. Factors Limiting Growth
  • 5.2.1. Costs and Experience Curve Effects
  • 5.2.2. The Role of ID Prevalence
  • 5.2.3. Wellness
  • 5.2.4. The Impact of Living Standards
• 5.3. Instrumentation, Automation and Diagnostic Trends
  • 5.3.1. Traditional Automation and Centralization
  • 5.3.2. The New Automation, Decentralization and Point Of Care
  • 5.3.3. Instruments Key to Market Share
  • 5.3.4. Bioinformatics Plays a Role
  • 5.3.5. PCR Takes Command
  • 5.3.6. Next Generation Sequencing Fuels a Revolution
  • 5.3.7. NGS Impact on Pricing
  • 5.3.8. Whole Genome Sequencing, A Brave New World
  • 5.3.9. Companion Diagnostics Blurs Diagnosis and Treatment

6. Clinical Laboratory MDx Infectious Disease Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Presymptom Health Nabs Funding for Sepsis Test
• 6.3. FDA Clears BioMerieux GI Panel
• 6.4. Rapid Infection Diagnostic Launches BSIDx
• 6.5. Biotia's AI-, Sequencing-Based UTI Test approved
• 6.6. Delve Bio, Broad Clinical Labs Partner for Metagenomic
• 6.7. Roche Respiratory Panel Receives FDA EUA
• 6.8. Genetic Signatures Gets Approval for GI Parasite Panel
• 6.9. Diasorin Expands Respiratory Panel
• 6.10. BioMerieux Outlines MDx-Driven Growth
• 6.11. T2 Biosystems Gets Extended T2Bacteria Panel
• 6.12. Diasorin Aims to Deliver Updated Instruments, New Assays
• 6.13. Oxford Nanopore Nabs Investment From BioMerieux
• 6.14. Day Zero Diagnostics Closes Financing Round
• 6.15. Spindiag Seeks Investors for Rapid PCR System
• 6.16. Sorrento Therapeutics Nabs Contract for Dx Platform
• 6.17. Kephera Planning Menu of Infectious Disease Tests
• 6.18. Oxford Nanopore and BioMerieux to Develop IDDx
• 6.19. SD Biosensor Eyes Global Expansion
• 6.20. Selux Dx Next Gen Phenotyping Gets FDA Clearance
• 6.21. Takara Developing High-Throughput Multiplex Panels
• 6.22. BioGX Debuts New Point-of-Care Molecular Testing System
• 6.23. Nanopath MDx Platform Providing 15-Minute Results
• 6.24. ProtonDx Commercializing Rapid MDx Instrument
• 6.25. Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
• 6.26. Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
• 6.27. Accelerate Diagnostics Anticipates Growth
• 6.28. Lumos Diagnostics Expanding Test Portfolio
• 6.29. Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

7. Key Companies

• 7.1. Abbott Laboratories
• 7.2. Agilent
• 7.3. Altona Diagnostics
• 7.4. Anitoa
• 7.5. Autonomous Medical Devices
• 7.6. Beckman Coulter Diagnostics (Danaher)
• 7.7. Becton, Dickinson and Company
• 7.8. BioGX
• 7.9. Biomatik
• 7.10. bioMerieux Diagnostics
• 7.11. Bio-Rad Laboratories, Inc
• 7.12. Cepheid (Danaher)
• 7.13. Diasorin S.p.A.
• 7.14. DNAe
• 7.15. Flow Health
• 7.16. Global Access Diagnostics
• 7.17. Great Basin Scientific, Inc
• 7.18. Hologic
• 7.19. Novacyt
• 7.20. Novus Diagnostics
• 7.21. Oncimmune
• 7.22. One Codex
• 7.23. OraSure Technologies
• 7.24. Prometheus Laboratories
• 7.25. Qiagen
• 7.26. QuidelOrtho
• 7.27. R-Biopharm AG
• 7.28. Response Biomedical
• 7.29. Revvity
• 7.30. Roche Diagnostics
• 7.31. Siemens Healthineers
• 7.32. Thermo Fisher Scientific
• 7.33. Vela Diagnostics
• 7.34. Veredus Laboratories
• 7.35. YD Diagnostics
• 7.36. Zhejiang Orient Gene Biotech

8. The Global Market for Clinical Laboratory MDx Infectious Disease

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Application - Overview
  • 8.2.1. Table - Global Market by Application
  • 8.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Application - Base Year
  • 8.2.4. Chart - Global Market by Application - End Year
  • 8.2.5. Chart - Global Market by Application - Share by Year
  • 8.2.6. Chart - Global Market by Application - Segments Growth
• 8.3. Global Market by Place - Overview
  • 8.3.1. Table - Global Market by Place
  • 8.3.2. Chart - Global Market by Place - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Place - Base Year
  • 8.3.4. Chart - Global Market by Place - End Year
  • 8.3.5. Chart - Global Market by Place - Share by Year
  • 8.3.6. Chart - Global Market by Place - Segments Growth

9. Global Clinical Laboratory MDx Infectious Disease Markets - By Application

• 9.1. Respiratory
  • 9.1.1. Table Respiratory - by Country
  • 9.1.2. Chart - Respiratory Growth
• 9.2. Blood Borne Virus
  • 9.2.1. Table Blood Borne Virus - by Country
  • 9.2.2. Chart - Blood Borne Virus Growth
• 9.3. Transplant
  • 9.3.1. Table Transplant - by Country
  • 9.3.2. Chart - Transplant Growth
• 9.4. Hospital Acquired Infections
  • 9.4.1. Table Hospital Acquired Infections - by Country
  • 9.4.2. Chart - Hospital Acquired Infections Growth
• 9.5. Reproductive Health
  • 9.5.1. Table Reproductive Health - by Country
  • 9.5.2. Chart - Reproductive Health Growth
• 9.6. C19. Singleplex
  • 9.6.1. Table C19 Singleplex - by Country
  • 9.6.2. Chart - C19 Singleplex Growth
• 9.7. Meningitis
  • 9.7.1. Table Meningitis - by Country
  • 9.7.2. Chart - Meningitis Growth
• 9.8. Gastrointestinal
  • 9.8.1. Table Gastrointestinal - by Country
  • 9.8.2. Chart - Gastrointestinal Growth
• 9.9. Tropical
  • 9.9.1. Table Tropical - by Country
  • 9.9.2. Chart - Tropical Growth

10. Global Clinical Laboratory MDx Infectious Disease Markets - By Place

• 10.1. Hospital Lab
  • 10.1.1. Table Hospital Lab - by Country
  • 10.1.2. Chart - Hospital Lab Growth
• 10.2. Outpatient Lab
  • 10.2.1. Table Outpatient Lab - by Country
  • 10.2.2. Chart - Outpatient Lab Growth
• 10.3. Point of Care
  • 10.3.1. Table Point of Care - by Country
  • 10.3.2. Chart - Point of Care Growth
• 10.4. Other Place
  • 10.4.1. Table Other Place - by Country
  • 10.4.2. Chart - Other Place Growth

11. Appendices

• 11.1. Growth of Approved IVD Test Menu
• 11.2. Growth of Approved Average IVD Test Fee
• 11.3. The Most Used IVD Assays
• 11.4. The Highest Grossing Assays
• 11.5. Laboratory Fees Schedule